HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Juan C. Chachques Jorge C. Trainini Alain Carpentier Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chachques, J. C. Articles by Carpentier, A. Search for Related Content PubMed Articles by Chachques, J. C. Articles by Carpentier, A. Related Collections Molecular biology

---

Original Articles: Cardiovascular

Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM Trial): Clinical Feasibility Study

^a Department of Cardiovascular Surgery, Pompidou Hospital, Paris, France
^b Departments of Cardiology and Cardiovascular Surgery, Avellaneda Hospital, Buenos Aires, Argentine

Accepted for publication October 12, 2007.

^_* Address correspondence to Dr Chachques, Department of Cardiovascular Surgery, Georges Pompidou European Hospital, 20 rue Leblanc, Paris, 75015, France (Email: j.chachques{at}brs.aphp.fr).

Background: Cell transplantation for the regeneration of ischemic myocardium is limited by poor graft viability and low cell retention. In ischemic cardiomyopathy, the extracellular matrix is deeply altered; therefore, it could be important to associate a procedure aiming at regenerating myocardial cells and restoring the extracellular matrix function. We evaluated the feasibility and safety of intrainfarct cell therapy associated with a cell-seeded collagen scaffold grafted onto infarcted ventricles.

Methods: In 20 consecutive patients presenting with left ventricular postischemic myocardial scars and indication for coronary artery bypass graft surgery, bone marrow cells were implanted during surgery. In the last 10 patients, we added a collagen matrix seeded with bone marrow cells, placed onto the scar.

Results: There was no mortality and any related adverse events (follow-up 10 ± 3.5 months). New York Heart Association functional class improved in both groups from 2.3 ± 0.5 to 1.3 ± 0.5 (matrix, p = 0.0002) versus 2.4 ± 0.5 to 1.5 ± 0.5 (no matrix, p = 0.001). Left ventricular end-diastolic volume evolved from 142.4 ± 24.5 mL to 112.9 ± 27.3 mL (matrix, p = 0.02) versus 138.9 ± 36.1 mL to 148.7 ± 41 mL (no matrix, p = 0.57), left ventricular filling deceleration time improved significantly in the matrix group from 162 ± 7 ms to 198 ± 9 ms (p = 0.01) versus the no-matrix group (from 159 ± 5 ms to 167 ± 8 ms, p = 0.07). Scar area thickness progressed from 6 ± 1.4 to 9 mm ± 1.1 mm (matrix, p = 0.005) versus 5 ± 1.5 mm to 6 ± 0.8 mm (no matrix, p = 0.09). Ejection fraction improved in both groups, from 25.3% ± 7.3% to 32% ± 5.4% (matrix, p = 0.03) versus 27.2% ± 6.9% to 34.6% ± 7.3% (no matrix, p = 0.031).

Conclusions: This tissue-engineered approach is feasible and safe and appears to improve the efficiency of cellular cardiomyoplasty. The cell-seeded collagen matrix increases the thickness of the infarct scar with viable tissue and helps to normalize cardiac wall stress in injured regions, thus limiting ventricular remodeling and improving diastolic function.